Alkermes Drug Patent Portfolio

Alkermes owns 1 orange book drug protected by 19 US patents Given below is the list of Alkermes's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7919499 Naltrexone long acting formulations and methods of use 15 Oct, 2029
Active
US6495164 Preparation of injectable suspensions having improved injectability 25 May, 2020 Expired
US6667061 Preparation of injectable suspensions having improved injectability 25 May, 2020 Expired
US7799345 Preparation of injectable suspensions having improved injectability 25 May, 2020 Expired
US6264987 Method for preparing microparticles having a selected polymer molecular weight 19 May, 2020 Expired
US6379704 Method for preparing microparticles having a selected polymer molecular weight 19 May, 2020 Expired
US6534092 Method for preparing microparticles having a selected polymer molecular weight 19 May, 2020 Expired
US6331317 Apparatus and method for preparing microparticles 12 Nov, 2019 Expired
US6395304 Apparatus and method for preparing microparticles 12 Nov, 2019 Expired
US6495166 Apparatus and method for preparing microparticles using in-line solvent extraction 12 Nov, 2019 Expired
US6537586 Apparatus and method for preparing microparticles 12 Nov, 2019 Expired
US6713090 Apparatus and method for preparing microparticles 12 Nov, 2019 Expired
US6939033 Method and apparatus for preparing microparticles using in-line solvent extraction 12 Nov, 2019 Expired
US6194006 Preparation of microparticles having a selected release profile 30 Dec, 2018 Expired
US6379703 Preparation of microparticles having a selected release profile 30 Dec, 2018 Expired
US6596316 Preparation of microparticles having a selected release profile 30 Dec, 2018 Expired
US5792477 Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent 02 May, 2017 Expired
US5916598 Preparation of biodegradable, biocompatible microparticles containing a biologically active agent 02 May, 2017 Expired
US6403114 Preparation of biodegradable, biocompatible microparticles containing a biologically active agent 02 May, 2017 Expired


Given below is the list of recent legal activities going on the following drug patents of Alkermes.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 05 Oct, 2022 US7919499
Payment of Maintenance Fee, 12th Year, Large Entity 21 Mar, 2022 US7799345
Termination or Final Written Decision 31 Jul, 2019 US7919499
Request for Trial Granted 07 Nov, 2018 US7919499
Payment of Maintenance Fee, 8th Year, Large Entity 05 Oct, 2018 US7919499
Petition Requesting Trial 20 Apr, 2018 US7919499
Payment of Maintenance Fee, 8th Year, Large Entity 21 Mar, 2018 US7799345
Patent Issue Date Used in PTA Calculation 05 Apr, 2011 US7919499
Recordation of Patent Grant Mailed 05 Apr, 2011 US7919499
Email Notification 17 Mar, 2011 US7919499
Issue Notification Mailed 16 Mar, 2011 US7919499
Dispatch to FDC 04 Mar, 2011 US7919499
Application Is Considered Ready for Issue 04 Mar, 2011 US7919499
Issue Fee Payment Verified 01 Mar, 2011 US7919499
Issue Fee Payment Received 01 Mar, 2011 US7919499


Alkermes's Drug Patent Litigations

Alkermes's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 31, 2016, against patent number US6667061. The petitioner Luye Pharma Group Ltd., challenged the validity of this patent, with Alkermes Controlled Therapeutics, Inc. as the respondent. Click below to track the latest information on how companies are challenging Alkermes's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7919499 April, 2018 Terminated-Settled
(31 Jul, 2019)
Alkermes Pharma Ireland Limited Amneal Pharmaceuticals LLC
US6667061 May, 2016 FWD Entered
(28 Nov, 2017)
Alkermes Controlled Therapeutics, Inc. Luye Pharma Group Ltd.
US6667061 May, 2016 Terminated-Denied
(30 Nov, 2016)
Alkermes Controlled Therapeutics, Inc. Luye Pharma Group Ltd.


Alkermes's Family Patents

Alkermes drugs have patent protection in a total of 11 countries. It has a significant patent presence in the US with 54.8% of its patents being US patents. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Alkermes Drug List

Given below is the complete list of Alkermes's drugs and the patents protecting them.


1. Vivitrol

Vivitrol is protected by 19 patents, out of which 18 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7919499 Naltrexone long acting formulations and methods of use 15 Oct, 2029
(4 years from now)
Active
US6495164 Preparation of injectable suspensions having improved injectability 25 May, 2020
(4 years ago)
Expired
US6667061 Preparation of injectable suspensions having improved injectability 25 May, 2020
(4 years ago)
Expired
US7799345 Preparation of injectable suspensions having improved injectability 25 May, 2020
(4 years ago)
Expired
US6264987 Method for preparing microparticles having a selected polymer molecular weight 19 May, 2020
(4 years ago)
Expired
US6379704 Method for preparing microparticles having a selected polymer molecular weight 19 May, 2020
(4 years ago)
Expired
US6534092 Method for preparing microparticles having a selected polymer molecular weight 19 May, 2020
(4 years ago)
Expired
US6331317 Apparatus and method for preparing microparticles 12 Nov, 2019
(5 years ago)
Expired
US6395304 Apparatus and method for preparing microparticles 12 Nov, 2019
(5 years ago)
Expired
US6495166 Apparatus and method for preparing microparticles using in-line solvent extraction 12 Nov, 2019
(5 years ago)
Expired
US6537586 Apparatus and method for preparing microparticles 12 Nov, 2019
(5 years ago)
Expired
US6713090 Apparatus and method for preparing microparticles 12 Nov, 2019
(5 years ago)
Expired
US6939033 Method and apparatus for preparing microparticles using in-line solvent extraction 12 Nov, 2019
(5 years ago)
Expired
US6194006 Preparation of microparticles having a selected release profile 30 Dec, 2018
(5 years ago)
Expired
US6379703 Preparation of microparticles having a selected release profile 30 Dec, 2018
(5 years ago)
Expired
US6596316 Preparation of microparticles having a selected release profile 30 Dec, 2018
(5 years ago)
Expired
US5792477 Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent 02 May, 2017
(7 years ago)
Expired
US5916598 Preparation of biodegradable, biocompatible microparticles containing a biologically active agent 02 May, 2017
(7 years ago)
Expired
US6403114 Preparation of biodegradable, biocompatible microparticles containing a biologically active agent 02 May, 2017
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vivitrol's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Alkermes News

Alkermes witnesses a 10% rise in share price due to positive updates on Lybalvi - Fierce Pharma

15 Feb, 2024

See More